Latest changes
This category tracks 375 sources on GovPing, covering Guidance, Enforcement, Rule, FAQ, Notice, and Consultation instruments across 3,297 total sources. There were 1,626 changes in the last 7 days.
The California Board of Pharmacy revoked 12 licenses effective April 1, 2026. Dr. Gerald Buchoff was ordered to pay $7,500 for negligence in treating a Yorkshire Terrier. Health Canada recalled Max Slim capsules for undeclared caffeine, and ANSM recalled 847 Namic syringes over burn risks.
Patent for Heterocyclic Compound Organic Light Emitting Device
The USPTO has published a patent application for a heterocyclic compound intended for use in organic light-emitting devices. The application, filed by Eui-Jeong Choi and others, describes a compound that may improve device efficiency and lifespan.
Patent Application: Organic Light Emitting Device Compound
The USPTO has published a new patent application, US20260090199A1, detailing a novel organic compound for use in organic light-emitting devices. The application describes a compound that may offer improved driving voltage, efficiency, and service life compared to existing technologies.
Mitsubishi Gas Chemical Organic Thin Film Patent Application
The USPTO has published a new patent application from Mitsubishi Gas Chemical Company, Inc. for a compound and organic thin film technology. The application, filed on December 14, 2023, details a specific molecular structure intended for use in photoelectric conversion elements and imaging devices.
Organic electronic element and compound for improved hole transport
The USPTO has published a new patent application, US20260090270A1, filed by TOSOH CORPORATION. The application describes an organic electronic element and a compound designed to improve hole transport ability, potentially enhancing performance in electronic devices.
Organic Compound and Light-Emitting Device Patent Application
The USPTO has published a patent application (US20260090268A1) for an organic compound and a light-emitting device incorporating it. The application details specific chemical structures and their application in electronic apparatus. The filing date was September 8, 2025.
USPTO Patent Application for Cancer Prodrugs
The USPTO has published a patent application (US20260085069A1) for novel prodrug compounds designed to treat cancer and other diseases by inhibiting Casein Kinase 2 alpha (CK2α). The application details specific chemical structures and their potential pharmaceutical uses.
Pritelivir Crystalline Form Patent Application
The USPTO has published a patent application (US20260085068A1) filed by Assembly Biosciences, Inc. on August 28, 2023. The application describes a novel crystalline form of the antiviral drug pritelivir, intended for the treatment of herpes virus.
Cyclic Sulfonamide RNR Inhibitors for Cancer Treatment
The USPTO has published a new patent application, US20260085067A1, detailing cyclic sulfonamide RNR inhibitors for cancer treatment. The application was filed on September 12, 2023, by inventors Anthony B. Pinkerton, Jacques Mauger, and Yen Pham Hong Truong.
LRRK2 Degrading Compounds for Parkinson's Disease Treatment
The USPTO has published a new patent application (US20260085066A1) detailing bifunctional compounds designed to degrade LRRK2, a protein implicated in Parkinson's Disease. The application covers pharmaceutical compositions and methods for treating LRRK2-associated disorders.
Patent for SGLT Inhibitor Synthesis Intermediate
The USPTO has published a patent application for a crystalline form of an intermediate useful in the synthesis of SGLT inhibitors. The application details a method to improve purification efficiency and minimize related substances in the final product, potentially increasing yield.
Patent Application: Benzofuranyl/Benzoxazolyl Compounds for Cancer Treatment
The USPTO has published a patent application (US20260085064A1) for substituted benzofuranyl and benzoxazolyl compounds, including their synthesis and use in treating cancer. The application was filed on May 2, 2025, by inventors from institutions including the University of Texas MD Anderson Cancer Center.
Patent Application: Benzamide Compounds for SARS-CoV-2 PLpro Inhibition
The USPTO has published a new patent application (US20260085063A1) detailing benzamide compounds and methods for inhibiting SARS-CoV-2 PLpro. The application was filed on August 19, 2025, by inventors Jun Wang, Bin Tan, and Prakash Daulat Jadhav.
Novel compounds as CK2 inhibitors for disease treatment
The USPTO has published a patent application (US20260085062A1) for novel compounds identified as CK2 inhibitors. These compounds are intended for the treatment and prevention of various diseases, including cancer, viral infections, and neurodegenerative disorders. The application details specific chemical structures and their potential pharmaceutical uses.
Patent Application: Phthalazine Derivatives as Pyruvate Kinase Modulators
The USPTO has published a new patent application (US20260085061A1) for phthalazine derivatives as pyruvate kinase modulators, assigned to Sitryx Therapeutics Limited. The application was filed on September 25, 2025.
Patent Application: Therapeutic Compounds - Orexin-1 Receptor Antagonists
The USPTO has published a new patent application (US20260085060A1) for therapeutic compounds that act as orexin-1 receptor antagonists. The application, filed on September 25, 2025, details compounds with structural formula (I), their preparation, and pharmaceutical uses.
System for updating medical facility uses AI
The USPTO has published a patent application for a system that uses AI to determine whether to update a medical facility. The system retrieves information from the facility, applies an AI model, and initiates maintenance or upgrades based on the determination. The application was filed on September 4, 2023.
Patent Application US20260085058A1 for SOS1 Degraders Treating Cancers
The USPTO has published patent application US20260085058A1, which relates to compounds that degrade son of sevenless homolog 1 (SOS1) and their use in treating cancers, particularly KRAS-mutant cancers. The application was filed on August 11, 2023.
OX1 Receptor Antagonists Patent Application
The USPTO has published a new patent application (US20260085056A1) filed on May 9, 2025, by NXERA PHARMA UK LIMITED. The application relates to novel compounds for treating neurological or psychiatric disorders associated with orexin receptors.
Patent Application for Recyclable Polymer Material and Monomer
The USPTO has published a patent application (US20260085055A1) for a novel monomer and a chemically recyclable polymer material comprising the same. The application, filed by the Korea Institute of Science and Technology, describes a monomer formed by bonding a pentagonal cyclic olefin molecule with a photosensitive molecule to enable chemical recycling.
Hispidin Derivative Synthesis Method and Use
The USPTO has published a patent application (US20260085054A1) detailing a new method for synthesizing Hispidin derivatives and their use in preparing lipid-lowering drugs. The application describes a process using readily available starting materials with potential for large-scale industrial application.
Patent Application for Benzofuran Derivatives as SIK Inhibitors
The USPTO has published a patent application (US20260085053A1) from BEONE MEDICINES I GMBH for benzofuran derivatives that act as SIK inhibitors. These compounds are intended for the treatment of various inflammatory diseases.
Patent Application for Furan Derivative Oxidation Process
The USPTO has published a patent application (US20260085052A1) detailing a new process for producing 2,5-furandicarboxylic acid. The application, filed by David Lee Sikkenga and Jan Hendrik Blank, describes a specific oxidation method involving furan derivatives, oxidants, solvents, and catalysts.
Patent Application for 2-Chloro-4-Fluoro-5-Nitrobenzoic Acid Preparation
The USPTO has published a patent application (US20260085051A1) detailing a novel nitration process for preparing 2-chloro-4-fluoro-5-nitrobenzoic acid. The assignee is ADAMA AGAN LTD. This compound is used in the synthesis of the herbicide saflufenacil.
Triple Kinase Inhibitors for Cancer Treatment
The USPTO has published a patent application (US20260085050A1) for triple kinase inhibitor compounds designed for cancer treatment. The application details compounds that inhibit EGFR, ALK, and MET simultaneously, along with methods for treating cancer using these inhibitors.
Ergothioneine Crystal Form Patent Application
The USPTO has published a patent application (US20260085049A1) for a novel crystal form of ergothioneine and its preparation method. The application details a method for producing high-purity ergothioneine with low moisture content, intended for use in dietary supplements, foods, and cosmetics.
ACSS2 Inhibitors for Cancer, Alcoholism, Viral Infections
The USPTO has published a patent application (US20260085048A1) detailing novel ACSS2 inhibitors and their potential uses in treating cancer, alcoholism, and viral infections. The application was filed on September 8, 2025.
Triphenylazole Compound Patent Application for Synucleinopathy Treatment
The USPTO has published a patent application (US20260085047A1) filed by Shiratori Pharmaceutical Co., Ltd. for a triphenylazole compound intended for the treatment or prevention of synucleinopathy. The application details the compound's structure and its potential use in pharmaceutical compositions.
Patent Application: Dual Function Compounds for Cancer Treatment
The USPTO has published patent application US20260085046A1, filed on August 7, 2025, for dual function compounds intended for cancer treatment. The application discloses compounds of Formula (I) and their use in treating cancer.
Patent Application for Nitrogen-Containing Heterocyclic Derivative Inhibitor
The USPTO has published a patent application (US20260085045A1) for a nitrogen-containing heterocyclic derivative inhibitor. The application details a compound, its preparation method, and its use in treating diseases such as cardiovascular and cerebrovascular conditions.
Salts and Solid Forms of 4-hydroxy-N,N-diisopropyltryptamine
The USPTO has published a patent application detailing new salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DIPT), including hemi-glutarate and hemi-succinate forms. These forms are disclosed for their potential use in treating neurological and psychiatric disorders.
Patent Application for 4-Amino-5-Methyl Pyridin-2-One Production Process
The USPTO has published a patent application (US20260085044A1) detailing an improved process for producing 4-amino-5-methyl-(1H)-pyridin-2-one and its derivatives. The application, filed by MinAscent Technologies GmbH, describes a method using ammonium salts under pressure without gaseous ammonia, aiming for high yield and purity while reducing container corrosion.
Patent Application: Initiator Mixture and Polymer Composition
The USPTO has published a new patent application (US20260085043A1) detailing an initiator mixture, a composition including it, and a polymer formed from the composition. The application was filed on September 18, 2025, by inventors from South Korea.
Method for Preparing Indigo or Substituted Derivative
The USPTO has published a patent application (US20260085042A1) detailing a method for synthesizing indigo or substituted derivatives. The application, filed on June 16, 2023, describes a process involving anthranilic acid and glyoxylic acid under hydrogenation with a metal catalyst.
Substituted Indazoles for Treating Animal Allergic Inflammatory Diseases
The USPTO has published a patent application detailing the use of substituted indazoles for the treatment and prevention of allergic and inflammatory diseases in animals. The application, filed on October 9, 2025, outlines specific compounds and their potential applications in veterinary medicine.
Patent Application for Cancer Treatment Compounds
The USPTO has published a new patent application (US20260085070A1) for heterocyclic CBL-B inhibitors intended for the treatment of cancer. The application was filed on April 7, 2025, by inventors Yingzhi BI, Kenneth G. CARSON, and Geraldine Cirillo HARRIMAN.
Patent Application for Novel Crystalline Form of Amine Compound
The USPTO has published a patent application (US20260085071A1) for novel crystalline forms of an amine compound, 1-(8-bromopyrido[2,3-e][1,2,4]triazolo[4,3-a]pyrazin-4-yl)-N-methylazetidin-3-amine. The application also discloses pharmaceutical compositions and the use of these forms for treating diseases such as atopic dermatitis and urticaria.
Protein Degraders Patent Application
The USPTO has published a new patent application, US20260085075A1, related to protein degraders and their uses. The application was filed on August 19, 2025, by inventors Nello Mainolfi, Nan Ji, Yi Zhang, and Matthew M. Weiss.
Patent Application for Novel Compound Treating Neurodegeneration and Cardiovascular Diseases
The USPTO has published a patent application (US20260085083A1) for a novel compound and pharmaceutical composition developed by SHANDONG RUZHI BIOMEDICINE TECHNOLOGY CO., LTD. The compound is intended for preventing or treating neurodegenerative diseases and cardiovascular/cerebrovascular diseases.
New Polymers and Methods Patent Application
The USPTO has published a new patent application, US20260085336A1, detailing processes for forming pyridinedicarboxylic acid derivatives and copolymers. The application, filed on September 25, 2025, outlines biocatalytic methods and potential uses for these new materials.
Novel Nootropic Prodrugs of Phenethylamine
The USPTO has published a patent application (US20260085036A1) for novel nootropic prodrugs of phenethylamine, assigned to MiHKAL GmbH. The application describes compounds designed to improve phenethylamine uptake and reduce side effects, potentially for treating conditions like depression and PTSD.
Psilocin Crystalline Forms Patent Application
The USPTO has published a patent application (US20260085039A1) detailing crystalline forms of psilocin, including salts and cocrystals. The application, filed by Jim Gilligan and Peter Guzzo, describes these forms as having improved physical properties like aqueous solubility and stability, suitable for various administration routes.
Photoresist Molecular Group Structure, Synthesis, and Use Method
The USPTO has published a new patent application (US20260086460A1) for a bifunctional molecular group structure for photoresists, including a linker, PAG molecule, and PDQ molecule. The application also details synthesis and use methods for this structure, assigned to Shanghai Huali Integrated Circuit Corporation.
Method for Preparing Intermediate of Adrenergic Receptor Agonist
The USPTO has published a patent application detailing a new method for preparing an intermediate of an adrenergic receptor agonist. The method claims to offer improved yield, reduced cost, and milder reaction conditions, making it more favorable for commercial production. The application was filed on December 4, 2025.
US Patent Application for Needle Locator and Guide
The USPTO has published a new patent application (US20260083950A1) for an apparatus designed to locate a target structure within a subject's body and guide a needle at a specific angle. The application was filed on September 1, 2023, by inventors Wim Bervoets, Daniel Smyth, Wolfram Frederik Dueck, and Jessica Brand.
Auto injector with reconstitution handling support patent
The USPTO has published a new patent application, US20260083917A1, for an auto-injector with reconstitution handling support. The patent describes a device designed to mix medicament components within the auto-injector before administration, with a processing unit controlling the mixing process and providing an onset signal.
Tamper Resistant Syringe Assembly Patent Application
The USPTO has published a patent application (US20260083918A1) for a tamper-evident and tamper-resistant syringe assembly filed by Civica, Inc. The application describes devices and methods to prevent tampering with pre-filled syringes and provide evidence of attempted access.
USPTO Patent Application for Medicine Injecting Needle Module
The USPTO has published a new patent application (US20260083919A1) for a medicine injecting needle module filed by AGNES MEDICAL CO.,LTD. The application details a needle module designed for efficient medicine delivery.
Split-Luer Lock Connector Patent Application
The USPTO has published a new patent application, US20260083920A1, for a Split-Luer Lock Connector. The application, filed on September 8, 2025, describes a male Luer coupler designed to facilitate peripheral device coupling to a host device.
Patent Application for Hot Air Curing Adhesive Method
The USPTO has published a patent application (US20260083921A1) for a method of curing adhesive with hot air treatment during the assembly of glass syringes. The application, filed by ATS Corporation, details a process involving dispensing, arranging, radiation curing, and hot air heating steps.
USPTO Patent Application for Atomizing Body Assembly
The USPTO has published a patent application (US20260083922A1) for an atomizing body assembly and soft mist device with improved sealing performance. The application details an assembly including a T-shaped steel member, chip-mounting part, filter cartridge, and O-ring designed to enhance sealing. The filing date was October 31, 2022.
Get daily alerts for healthcare & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
1,641 changes in last 7 days
Latest high priority updates
Browse Categories
375 official sources tracked
Get Healthcare & Life Sciences alerts
Daily digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get Healthcare & Life Sciences alerts
We'll email you when new healthcare & life sciences changes are detected.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.